{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T11:39:26.850963+00:00","company":{"ticker":"EOLS","cik":1570562,"company_name":"Evolus, Inc."},"pagination":{"limit":100,"returned":41,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"BPCR Limited Partnership, BioPharma Credit Investments V LP, and Biopharma Credit PLC","detail":"credit_facility","count":2,"first_seen":"2022-12-08T23:59:59+00:00","last_seen":"2023-05-09T23:59:59+00:00","evidence_fact_ids":[156181,192408]},{"display_name":"Daewoong Pharmaceuticals Co., Ltd.","detail":"license","count":1,"first_seen":"2022-12-13T23:59:59+00:00","last_seen":"2022-12-13T23:59:59+00:00","evidence_fact_ids":[191517]},{"display_name":"Eclipse Business Capital LLC, as administrative agent, and the lenders party thereto","detail":"credit_facility","count":1,"first_seen":"2026-03-03T23:59:59+00:00","last_seen":"2026-03-03T23:59:59+00:00","evidence_fact_ids":[30287]},{"display_name":"Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A","detail":"underwriting","count":1,"first_seen":"2024-03-13T23:59:59+00:00","last_seen":"2024-03-13T23:59:59+00:00","evidence_fact_ids":[67922]},{"display_name":"Symatese Aesthetics S.A.S.","detail":"license","count":1,"first_seen":"2023-12-20T23:59:59+00:00","last_seen":"2023-12-20T23:59:59+00:00","evidence_fact_ids":[86960]},{"display_name":"Symatese S.A.S","detail":"license","count":1,"first_seen":"2023-05-09T23:59:59+00:00","last_seen":"2023-05-09T23:59:59+00:00","evidence_fact_ids":[156180]}],"lender":[{"display_name":"BPCR Limited Partnership, BioPharma Credit Investments V LP","detail":"term_loan","count":2,"first_seen":"2022-12-08T23:59:59+00:00","last_seen":"2025-05-05T23:59:59+00:00","evidence_fact_ids":[96833,192410]},{"display_name":"BPCR Limited Partnership and BioPharma Credit Investments V LP","detail":"term_loan","count":1,"first_seen":"2023-05-09T23:59:59+00:00","last_seen":"2023-05-09T23:59:59+00:00","evidence_fact_ids":[156182]},{"display_name":"Eclipse Business Capital LLC","detail":"revolving_credit","count":1,"first_seen":"2026-03-03T23:59:59+00:00","last_seen":"2026-03-03T23:59:59+00:00","evidence_fact_ids":[32826]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"3562fcd3424604929ef2d6ea735037985236d502","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2026-06-12T20:19:03+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-11","outcome":"passed","proposal_text":"Advisory approval of named executive officer compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"11,183,774","subject":null,"votes_abstain":"441,629","votes_against":"336,958","votes_for":"39,350,651","votes_withheld":null}]},"claim":"Evolus, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2026-06-11 meeting.","evidence_excerpt":"The stockholders of the Company approved, on an advisory basis, the compensation of the Company’s named executive officers.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-26-000076","anchor_url":"https://secwatch.observer/filing/0001570562-26-000076#claim-3562fcd3424604929ef2d6ea735037985236d502","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000076/0001570562-26-000076-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0140ea684a123c535feff80724428ee786012d2f","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2026-06-12T20:19:03+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-11","outcome":"passed","proposal_text":"Ratification of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"18,696","votes_against":"63,992","votes_for":"51,230,324","votes_withheld":null}]},"claim":"Evolus, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-06-11 meeting.","evidence_excerpt":"The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-26-000076","anchor_url":"https://secwatch.observer/filing/0001570562-26-000076#claim-0140ea684a123c535feff80724428ee786012d2f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000076/0001570562-26-000076-index.htm"},{"fact_type":"shareholder_vote","fact_key":"915ebf48fc9a597cbfffe5a6578b43c68ff23068","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2026-06-12T20:19:03+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-11","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"11,183,774","subject":"Brady Stewart","votes_abstain":null,"votes_against":null,"votes_for":"38,479,626","votes_withheld":"1,662,228"},{"broker_non_votes":"11,183,774","subject":"Vikram Malik","votes_abstain":null,"votes_against":null,"votes_for":"21,310,653","votes_withheld":"18,831,201"}]},"claim":"Evolus, Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.","evidence_excerpt":"The stockholders of the Company elected each of Brady Stewart and Vikram Malik as Class II directors for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029 and until each of their successors has been duly elected and qualified, or until their earlier death, resignation or removal.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-26-000076","anchor_url":"https://secwatch.observer/filing/0001570562-26-000076#claim-915ebf48fc9a597cbfffe5a6578b43c68ff23068","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000076/0001570562-26-000076-index.htm"},{"fact_type":"earnings_release","fact_key":"c3ba6f5cee177c918c92f4be8e28d3527e255f08","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$73.1 million"},"claim":"Evolus, Inc. reported the first quarter ended March 31, 2026 results: revenue $73.1 million. Guidance reaffirmed.","evidence_excerpt":"Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook • Global Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025 • GAAP Operating Loss of $6.8 Million and Adjusted EBITDA of $0.6 Million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-26-000064","anchor_url":"https://secwatch.observer/filing/0001570562-26-000064#claim-c3ba6f5cee177c918c92f4be8e28d3527e255f08","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/0001570562-26-000064-index.htm"},{"fact_type":"debt_financing","fact_key":"0a8a0ae47d473fe6453878d194ece53d5179f8f5","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2026-03-03T23:59:59+00:00","payload":{"counterparty":"Eclipse Business Capital LLC","effective_date":"2026-03-03","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"adjusted term secured overnight financing rate (“SOFR”) (subject to a floor of 2","item_codes_triggered":["2.03"],"maturity_text":"March 3, 2029","principal_text":"up to $30.0 million"},"claim":"Evolus, Inc. incurred revolving credit of up to $30.0 million with Eclipse Business Capital LLC at adjusted term secured overnight financing rate (“SOFR”) (subject to a floor of 2 maturing March 3, 2029.","evidence_excerpt":"On March 3, 2026, Evolus, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Eclipse Business Capital LLC, as administrative agent (the “Agent”) and the lenders party thereto. The Loan Agreement provides for a senior secured asset-based revolving credit facility of up to $30.0 million (the “Revolving Credit Facility”), subject to a borrowing base formula based on eligible accounts receivable and eligible inventory, in each case reduced by customary reserves.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-013872","anchor_url":"https://secwatch.observer/filing/0001628280-26-013872#claim-0a8a0ae47d473fe6453878d194ece53d5179f8f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000162828026013872/0001628280-26-013872-index.htm"},{"fact_type":"material_agreement","fact_key":"0983fb6bac103ee998d53fb04346b58f8069e610","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2026-03-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Loan Agreement","agreement_type":"credit_facility","counterparty":"Eclipse Business Capital LLC, as administrative agent, and the lenders party thereto","effective_date":"2026-03-03","item_codes_triggered":["1.01"],"value_text":"up to $30.0 million"},"claim":"Evolus, Inc. entered into Loan Agreement with Eclipse Business Capital LLC, as administrative agent, and the lenders party thereto valued at up to $30.0 million (effective 2026-03-03).","evidence_excerpt":"On March 3, 2026, Evolus, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with Eclipse Business Capital LLC, as administrative agent (the “Agent”) and the lenders party thereto.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-013872","anchor_url":"https://secwatch.observer/filing/0001628280-26-013872#claim-0983fb6bac103ee998d53fb04346b58f8069e610","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000162828026013872/0001628280-26-013872-index.htm"},{"fact_type":"executive_change","fact_key":"0b13dbaa68","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2025-06-06T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Simone Blank departed as Director at Evolus, Inc..","evidence_excerpt":"Simone Blank voluntarily stepped down from the board of directors of the Company (the “Board”) effective on June 5, 2025, as part of a planned board refreshment and transition.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-25-000085","anchor_url":"https://secwatch.observer/filing/0001570562-25-000085#claim-0b13dbaa68","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000085/0001570562-25-000085-index.htm"},{"fact_type":"executive_change","fact_key":"59f8fa8d7a","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2025-05-27T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-06-13","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Sandra Beaver resigned as Chief Financial Officer at Evolus, Inc..","evidence_excerpt":"On May 27, 2025, Evolus, Inc. (the “Company”) announced that Sandra Beaver had informed the Company of her decision to voluntarily resign from her position as the Chief Financial Officer, effective as of June 13, 2025, to pursue another opportunity.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-25-000083","anchor_url":"https://secwatch.observer/filing/0001570562-25-000083#claim-59f8fa8d7a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000083/0001570562-25-000083-index.htm"},{"fact_type":"debt_financing","fact_key":"9e007daac9f25a5a364e8dc95c03395cb16d3ac6","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2025-05-05T23:59:59+00:00","payload":{"counterparty":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP","effective_date":"2025-05-05","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t","item_codes_triggered":["2.03"],"maturity_text":"5th year anniversary of the Tranche A Closing Date","principal_text":"up to $250,000,000"},"claim":"Evolus, Inc. incurred term loan of up to $250,000,000 with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP at 3-month Secured Overnight Financing Rate (“SOFR”) plus 5.0% per annum (subject t maturing 5th year anniversary of the Tranche A Closing Date.","evidence_excerpt":"the Lenders agreed to make term loans to the Company in an aggregate principal amount of up to $250,000,000","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-25-000069","anchor_url":"https://secwatch.observer/filing/0001570562-25-000069#claim-9e007daac9f25a5a364e8dc95c03395cb16d3ac6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056225000069/0001570562-25-000069-index.htm"},{"fact_type":"executive_change","fact_key":"42be985381","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2024-07-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert Hayman departed as Director at Evolus, Inc..","evidence_excerpt":"Robert Hayman voluntarily stepped down from the Board effective upon Mr. White’s appointment on July 1, 2024 as part of a planned board refreshment and transition.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-24-000104","anchor_url":"https://secwatch.observer/filing/0001570562-24-000104#claim-42be985381","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000104/0001570562-24-000104-index.htm"},{"fact_type":"executive_change","fact_key":"e292d7eb2c","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-07-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-07-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Albert G. White III was appointed as Director at Evolus, Inc..","evidence_excerpt":"The Board of Directors (the “Board”) of Evolus, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Committee”), appointed Albert G. White III as a member of the Board, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-24-000104","anchor_url":"https://secwatch.observer/filing/0001570562-24-000104#claim-e292d7eb2c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000104/0001570562-24-000104-index.htm"},{"fact_type":"earnings_release","fact_key":"334d4230bfcc129601d8a97b63d3d01877af513d","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$59.3 million"},"claim":"Evolus, Inc. reported the first quarter ended March 31, 2024 results: revenue $59.3 million. Guidance reaffirmed.","evidence_excerpt":"Total net revenues for the first quarter of 2024 increased 42% to $59.3 million from $41.7 million in the first quarter of 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-24-000078","anchor_url":"https://secwatch.observer/filing/0001570562-24-000078#claim-334d4230bfcc129601d8a97b63d3d01877af513d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000078/0001570562-24-000078-index.htm"},{"fact_type":"executive_change","fact_key":"da4a12978f","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-04-03T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Simone Blank departed as Director at Evolus, Inc..","evidence_excerpt":"Ms. Blank notified the Board that she will step down from her position on the earlier of: (i) the Company’s Annual Shareholder Meeting occurring in 2025, or (ii) the successful identification and appointment of a replacement director, whichever occurs first.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-24-000061","anchor_url":"https://secwatch.observer/filing/0001570562-24-000061#claim-da4a12978f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000061/0001570562-24-000061-index.htm"},{"fact_type":"executive_change","fact_key":"9f1b2c34dc","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-04-03T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Robert Hayman departed as Director at Evolus, Inc..","evidence_excerpt":"Mr. Hayman notified the Board that he will step down from his position on the successful identification and appointment of a replacement director.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-24-000061","anchor_url":"https://secwatch.observer/filing/0001570562-24-000061#claim-9f1b2c34dc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000061/0001570562-24-000061-index.htm"},{"fact_type":"material_agreement","fact_key":"352c65b062b907d04d10c29434847343bb180e46","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-03-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A","effective_date":"2024-03-11","item_codes_triggered":["1.01"],"value_text":"approximately $46.9 million"},"claim":"Evolus, Inc. entered into Underwriting Agreement with Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A valued at approximately $46.9 million (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Evolus, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners, LLC and Stifel, Nicolaus & Company, Incorporated as representatives of the underwriters named in Schedule A thereto (together, the “Underwriters”), in connection with the underwritten public offering, issuance and sale by the Company (the “Offering”) of 3,554,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-24-000049","anchor_url":"https://secwatch.observer/filing/0001570562-24-000049#claim-352c65b062b907d04d10c29434847343bb180e46","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000049/0001570562-24-000049-index.htm"},{"fact_type":"earnings_release","fact_key":"5f526b98844f73a015eb078dc5ff6457e5f38e5e","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2023","report_date":"2024-03-07","result_type":"reported_results","revenue_text":"$61.0 million"},"claim":"Evolus, Inc. reported the quarter and year ended December 31, 2023 results: revenue $61.0 million. Guidance reaffirmed.","evidence_excerpt":"of $2 Million Compared to Q3 • Full-Year 2023 Operating Expense of $163.9 Million in Alignment with Guidance Range of $160 Million to $165 Million • Global Net Revenue Record of $61.0 Million for the Fourth Quarter and $202.1 Million Full-Year 2023, Representing 40% and 36% Growth Over the Prior Year; These Results Are Unchanged from the Preliminary Results Reported","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-24-000038","anchor_url":"https://secwatch.observer/filing/0001570562-24-000038#claim-5f526b98844f73a015eb078dc5ff6457e5f38e5e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000038/0001570562-24-000038-index.htm"},{"fact_type":"earnings_release","fact_key":"8b105bb81d52d26ebcfc85e699f29955246d06e5","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2024-01-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2023","report_date":"2024-01-16","result_type":"preliminary_results","revenue_text":null},"claim":"Evolus, Inc. updated its the quarter and year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"On January 16, 2024, the Company issued a press release announcing its preliminary, unaudited net revenue and certain other operational and financial data for the quarter and year ended December 31, 2023. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.","confidence":0.6,"filing_url":"https://secwatch.observer/filing/0001570562-24-000003","anchor_url":"https://secwatch.observer/filing/0001570562-24-000003#claim-8b105bb81d52d26ebcfc85e699f29955246d06e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056224000003/0001570562-24-000003-index.htm"},{"fact_type":"material_agreement","fact_key":"95de0803c3f48446c01846d6a7b07db1d7f843c6","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-12-20T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License, Supply and Distribution Agreement","agreement_type":"license","counterparty":"Symatese Aesthetics S.A.S.","effective_date":"2023-12-20","item_codes_triggered":["1.01"],"value_text":"610,000 shares of the Company’s common stock"},"claim":"Evolus, Inc. entered into License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S. valued at 610,000 shares of the Company’s common stock (effective 2023-12-20).","evidence_excerpt":"On December 20, 2023, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”) and Symatese Aesthetics S.A.S. (“Symatese”), entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which Symatese granted to Evolus Europe an exclusive right to commercialize and distribute four dermal filler product candidates","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000119","anchor_url":"https://secwatch.observer/filing/0001570562-23-000119#claim-95de0803c3f48446c01846d6a7b07db1d7f843c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/0001570562-23-000119-index.htm"},{"fact_type":"earnings_release","fact_key":"a3a6c514e2f523967c98032dc2f813b26325506e","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year 2023","report_date":null,"result_type":"guidance_update","revenue_text":null},"claim":"Evolus, Inc. updated its full year 2023 guidance (raised).","evidence_excerpt":"Evolus now expects total net revenues for the full year 2023 to be between $194 and $198 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-23-000114","anchor_url":"https://secwatch.observer/filing/0001570562-23-000114#claim-a3a6c514e2f523967c98032dc2f813b26325506e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000114/0001570562-23-000114-index.htm"},{"fact_type":"earnings_release","fact_key":"23ff266e8340e421e8ef7d6dfa6fdd2ee12c6ba1","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"three months ended September 30, 2023","report_date":null,"result_type":"reported_results","revenue_text":"$50.0 million"},"claim":"Evolus, Inc. reported three months ended September 30, 2023 results: revenue $50.0 million. Guidance raised.","evidence_excerpt":"Total net revenues for the third quarter of 2023 increased 48% to $50.0 million from $33.9 million in the third quarter of 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-23-000114","anchor_url":"https://secwatch.observer/filing/0001570562-23-000114#claim-23ff266e8340e421e8ef7d6dfa6fdd2ee12c6ba1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000114/0001570562-23-000114-index.htm"},{"fact_type":"earnings_release","fact_key":"9b6c83406e42c3edd152d8821c473643c70b5359","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-08-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter ended June 30, 2023","report_date":"2023-08-02","result_type":"reported_results","revenue_text":"$49.3 million"},"claim":"Evolus, Inc. reported the second quarter ended June 30, 2023 results: revenue $49.3 million. Guidance raised.","evidence_excerpt":"Total net revenues for the second quarter of 2023 increased 33% to $49.3 million from $37.2 million in the second quarter of 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-23-000086","anchor_url":"https://secwatch.observer/filing/0001570562-23-000086#claim-9b6c83406e42c3edd152d8821c473643c70b5359","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000086/0001570562-23-000086-index.htm"},{"fact_type":"earnings_release","fact_key":"12fda5a8bd0734c6236685ade59ae85a198362a0","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-07-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter ended June 30, 2023","report_date":"2023-07-27","result_type":"reported_results","revenue_text":"$49.3 million"},"claim":"Evolus, Inc. reported the second quarter ended June 30, 2023 results: revenue $49.3 million. Guidance raised.","evidence_excerpt":"Guidance on Record Second Quarter 2023 Revenue • Company Increases Full-Year 2023 Net Revenue Guidance to $185 to $195 Million • Company Achieved Quarterly Net Revenue of $49.3 Million, Growing 33% Year-over-Year and 10 Percentage Points Above the First Quarter’s Growth Rate • Achieved Record Growth and All-time Highs in New Accounts and Consumer Loyalty","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000082","anchor_url":"https://secwatch.observer/filing/0001570562-23-000082#claim-12fda5a8bd0734c6236685ade59ae85a198362a0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000082/0001570562-23-000082-index.htm"},{"fact_type":"governance_change","fact_key":"95e4129fca1a6d635d001f562d23c701a420f6f5","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2023-06-12","item_codes_triggered":["5.03"],"summary_text":"Increased authorized common shares from 100,000,000 to 200,000,000"},"claim":"Evolus, Inc.: Increased authorized common shares from 100,000,000 to 200,000,000 (effective 2023-06-12).","evidence_excerpt":"At the Annual Meeting the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock the Company is authorized to issue from 100,000,000 to 200,000,000 (the “Authorized Share Increase”). A Certificate of Amendment to the Company's Restated Certificate of Incorporation (the “Certificate of Amendment”) was filed with the Secretary of State of the State of Delaware to effect the Authorized Share Increase on June 12, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000079","anchor_url":"https://secwatch.observer/filing/0001570562-23-000079#claim-95e4129fca1a6d635d001f562d23c701a420f6f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000079/0001570562-23-000079-index.htm"},{"fact_type":"shareholder_vote","fact_key":"37ab0ee705df07060060928587d372b64f86e564","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-09","outcome":"passed","proposal_text":"Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"3,420","votes_against":"208,081","votes_for":"46,277,684","votes_withheld":null}]},"claim":"Evolus, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-06-09 meeting.","evidence_excerpt":"The results of the stockholders’ vote with respect to such ratification were as follows: For Against Abstain 46,277,684 208,081 3,420","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000079","anchor_url":"https://secwatch.observer/filing/0001570562-23-000079#claim-37ab0ee705df07060060928587d372b64f86e564","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000079/0001570562-23-000079-index.htm"},{"fact_type":"shareholder_vote","fact_key":"52300aef20baec7811811efdcc90ffc4f8502d0e","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-09","outcome":"passed","proposal_text":"Approval of Authorized Shares Increase","proposal_type":"charter_amendment","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"63,406","votes_against":"965,182","votes_for":"45,460,597","votes_withheld":null}]},"claim":"Evolus, Inc. shareholders approved Approval of Authorized Shares Increase at the 2023-06-09 meeting.","evidence_excerpt":"The results of the stockholders’ vote with respect to such approval were as follows: For Against Abstain 45,460,597 965,182 63,406","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000079","anchor_url":"https://secwatch.observer/filing/0001570562-23-000079#claim-52300aef20baec7811811efdcc90ffc4f8502d0e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000079/0001570562-23-000079-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a758905d929d3efc0b66744fec12a73dbb5213b8","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-06-14T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-06-09","outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":"10,092,887","subject":"Simone Blank","votes_abstain":null,"votes_against":null,"votes_for":"33,988,143","votes_withheld":"2,408,155"},{"broker_non_votes":"10,092,887","subject":"Brady Stewart","votes_abstain":null,"votes_against":null,"votes_for":"34,033,280","votes_withheld":"2,363,018"}]},"claim":"Evolus, Inc. shareholders approved Election of Class II Directors at the 2023-06-09 meeting.","evidence_excerpt":"The results of the stockholders’ vote with respect to the election of the Class II Directors were as follows: Nominee Term Expiring For Withhold Broker Non-Vote Simone Blank 2026 33,988,143 2,408,155 10,092,887 Brady Stewart 2026 34,033,280 2,363,018 10,092,887","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000079","anchor_url":"https://secwatch.observer/filing/0001570562-23-000079#claim-a758905d929d3efc0b66744fec12a73dbb5213b8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000079/0001570562-23-000079-index.htm"},{"fact_type":"earnings_release","fact_key":"1b1b7583b4c8f02dc1c74e7029e7fba7478edca4","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2023","report_date":"2023-05-09","result_type":"reported_results","revenue_text":"$41.7 million"},"claim":"Evolus, Inc. reported first quarter ended March 31, 2023 results: revenue $41.7 million. Guidance reaffirmed.","evidence_excerpt":"Evolus Reports First Quarter 2023 Results and Provides Business Update • Q1 2023 Net Revenue of $41.7 Million, Up 23% from Q1 2022 • Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million • Raises 2028 Revenue Outlook from $500 Million to $700 Million Driven by Addition of EvolysseTM Dermal Filler Line Representing a 29% CAGR • Fully Funded to Profitability, Including the Dermal Filler Investment, by Utilizing Remaining $50 Million of Pharmakon Credit Facility","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-23-000068","anchor_url":"https://secwatch.observer/filing/0001570562-23-000068#claim-1b1b7583b4c8f02dc1c74e7029e7fba7478edca4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000068/0001570562-23-000068-index.htm"},{"fact_type":"debt_financing","fact_key":"9b4b803684a23983424b7d620859a6bf52514581","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-05-09T23:59:59+00:00","payload":{"counterparty":"BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP","effective_date":"2023-05-09","event":"amendment","instrument_type":"term_loan","interest_rate_text":"SOFR","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":"$50.0 million"},"claim":"Evolus, Inc. amended term loan of $50.0 million with BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP at SOFR.","evidence_excerpt":"On May 9, 2023, the Company entered into a Third Amendment to Loan Agreement (the “Third Amendment”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender” and, together with BPCR Limited Partnership, the “Lenders”), and Biopharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), which amends certain terms of the Loan and Security Agreement, dated December 14, 2021, as amended, by and among the Company, Lenders, and Collateral Agent (the “Loan Agreement”). The Third Amendment provides that, subject to the terms of the Loan Agreement, as amended, the Lenders will advance the second tranche of $50.0 million to the Company in two installments: (i) $25.0 million to be advanced on May 31, 2023 and (ii) $25.0 million to be advanced on December 15, 2023. The Third Amendment increases the interest only period under the Loan Agreement by 12 months, after which the Company shall make seven equal quarterly","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000068","anchor_url":"https://secwatch.observer/filing/0001570562-23-000068#claim-9b4b803684a23983424b7d620859a6bf52514581","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000068/0001570562-23-000068-index.htm"},{"fact_type":"material_agreement","fact_key":"e93ad89f18f1a5205ca5924107eda2af811c3c0a","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-05-09T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Third Amendment to Loan Agreement","agreement_type":"credit_facility","counterparty":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC","effective_date":"2023-05-09","item_codes_triggered":["1.01"],"value_text":"$50.0 million"},"claim":"Evolus, Inc. amended Third Amendment to Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC valued at $50.0 million (effective 2023-05-09).","evidence_excerpt":"On May 9, 2023, the Company entered into a Third Amendment to Loan Agreement (the “Third Amendment”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender” and, together with BPCR Limited Partnership, the “Lenders”), and Biopharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent”), which amends certain terms of the Loan and Security Agreement, dated December 14, 2021, as amended, by and among the Company, Lenders, and Collateral Agent (the “Loan Agreement”). The Third Amendment provides that, subject to the terms of the Loan Agreement, as amended, the Lenders will advance the second tranche of $50.0 million to the Company in two installments","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000068","anchor_url":"https://secwatch.observer/filing/0001570562-23-000068#claim-e93ad89f18f1a5205ca5924107eda2af811c3c0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000068/0001570562-23-000068-index.htm"},{"fact_type":"material_agreement","fact_key":"04746aacb3b8473d1ce6f3ebb22dde809cc5733d","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-05-09T23:59:59+00:00","payload":{"action":"entry","agreement_name":"License, Supply and Distribution Agreement","agreement_type":"license","counterparty":"Symatese S.A.S","effective_date":"2023-05-09","item_codes_triggered":["1.01"],"value_text":"up to €16.2 million"},"claim":"Evolus, Inc. entered into License, Supply and Distribution Agreement with Symatese S.A.S valued at up to €16.2 million (effective 2023-05-09).","evidence_excerpt":"On May 9, 2023, Evolus, Inc. (the “Company”) and Symatese S.A.S (“Symatese”), entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which Symatese granted to the Company an exclusive right to commercialize and distribute its five dermal filler product candidates,which are referred to as: (i) Lift; (ii) Smooth; (iii) Sculpt; (iv) Lips; and (v) Eye (each, a “Product” and collectively, the “Products”) in the United States for use in the aesthetics and dermatological fields (the “Field”). The Company also has the right of first negotiation to obtain a license from Symatese to commercialize and distribute any new products developed using the same technology as the Products in the Field in the United States. As consideration for the rights granted under the Agreement, the Company is required to make up to €16.2 million in milestone payments to Symatese,","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000068","anchor_url":"https://secwatch.observer/filing/0001570562-23-000068#claim-04746aacb3b8473d1ce6f3ebb22dde809cc5733d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000068/0001570562-23-000068-index.htm"},{"fact_type":"earnings_release","fact_key":"870a4b6e14a316b9c2960db1b085ffde16e79172","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2022","report_date":null,"result_type":"reported_results","revenue_text":"Total net revenues for the fourth quarter of 2022 increased 26% to $43.6 million"},"claim":"Evolus, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue Total net revenues for the fourth quarter of 2022 increased 26% to $43.6 million. Guidance reaffirmed.","evidence_excerpt":"Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update • Q4 2022 Net Revenue Reached an All-Time High of $43.6 Million, Up 26% from Q4 2021 • Full-Year 2022 Net Revenue of $148.6 Million, Up 49% Over 2021 • Reaffirms Full-Year 2023 Net Revenue Guidance of $180 to $190 Million","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001570562-23-000034","anchor_url":"https://secwatch.observer/filing/0001570562-23-000034#claim-870a4b6e14a316b9c2960db1b085ffde16e79172","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000034/0001570562-23-000034-index.htm"},{"fact_type":"earnings_release","fact_key":"15a54a2b08e4cb86eb4733b1770c3db8916b3a6b","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2022","report_date":"2023-03-08","result_type":"reported_results","revenue_text":null},"claim":"Evolus, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On March 8, 2023, the Company issued a press release announcing its financial results for the quarter and year ended December 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-23-000034","anchor_url":"https://secwatch.observer/filing/0001570562-23-000034#claim-15a54a2b08e4cb86eb4733b1770c3db8916b3a6b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000034/0001570562-23-000034-index.htm"},{"fact_type":"earnings_release","fact_key":"371e6a8696c9dca939cd540b1fe796a54775580a","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2023-01-18T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2022","report_date":"2023-01-18","result_type":"preliminary_results","revenue_text":null},"claim":"Evolus, Inc. updated its the quarter and year ended December 31, 2022 guidance (initiated).","evidence_excerpt":"On January 18, 2023, the Company issued a press release announcing its preliminary, unaudited net revenue and certain other operational and financial data for the quarter and year ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-23-000003","anchor_url":"https://secwatch.observer/filing/0001570562-23-000003#claim-371e6a8696c9dca939cd540b1fe796a54775580a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000003/0001570562-23-000003-index.htm"},{"fact_type":"material_agreement","fact_key":"789d1d0b41906534d9cf5750c850761f4419904a","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-12-13T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Fourth Amendment to License and Supply Agreement","agreement_type":"license","counterparty":"Daewoong Pharmaceuticals Co., Ltd.","effective_date":"2022-12-12","item_codes_triggered":["1.01"],"value_text":null},"claim":"Evolus, Inc. amended Fourth Amendment to License and Supply Agreement with Daewoong Pharmaceuticals Co., Ltd. (effective 2022-12-12).","evidence_excerpt":"On December 12, 2022, Evolus, Inc., a Delaware corporation (the “Company”), and Daewoong Pharmaceuticals Co., Ltd., a corporation organized and existing under the laws of the Republic of Korea (“Daewoong”) entered into a Fourth Amendment (the “Fourth Amendment”) to that certain License and Supply Agreement (the “Supply Agreement”), originally dated September 30, 2013, as amended.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-22-000149","anchor_url":"https://secwatch.observer/filing/0001570562-22-000149#claim-789d1d0b41906534d9cf5750c850761f4419904a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/0001570562-22-000149-index.htm"},{"fact_type":"debt_financing","fact_key":"a872d087a82f8c2e4ea93843d82874ce8671dd06","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-12-08T23:59:59+00:00","payload":{"counterparty":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP","effective_date":"2022-12-05","event":"amendment","instrument_type":"term_loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":null},"claim":"Evolus, Inc. amended term loan with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP.","evidence_excerpt":"On December 5, 2022, Evolus, Inc. (the “Company”) entered into a Second Amendment to Loan Agreement (the “Second Amendment”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender” and, together with BPCR Limited Partnership, the “Lenders”), and Biopharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent), which amends certain terms of the Loan and Security Agreement, dated December 14, 2021, as amended, by and among the Company, Lenders, and Collateral Agent (the “Loan Agreement”). The Second Amendment extends the Company’s option to draw down the second tranche of $50 million of the term loan facility provided under the Loan Agreement until December 31, 2023 (the “Draw Period”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-22-000146","anchor_url":"https://secwatch.observer/filing/0001570562-22-000146#claim-a872d087a82f8c2e4ea93843d82874ce8671dd06","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000146/0001570562-22-000146-index.htm"},{"fact_type":"material_agreement","fact_key":"23e2f2e21ba81e12e60b1a74e992d2a91e99b1f1","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-12-08T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Second Amendment to Loan Agreement","agreement_type":"credit_facility","counterparty":"BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC","effective_date":"2022-12-05","item_codes_triggered":["1.01"],"value_text":"$50 million"},"claim":"Evolus, Inc. amended Second Amendment to Loan Agreement with BPCR Limited Partnership, BioPharma Credit Investments V (Master) LP, and Biopharma Credit PLC valued at $50 million (effective 2022-12-05).","evidence_excerpt":"On December 5, 2022, Evolus, Inc. (the “Company”) entered into a Second Amendment to Loan Agreement (the “Second Amendment”) with BPCR Limited Partnership (as a “Lender”), BioPharma Credit Investments V (Master) LP (as a “Lender” and, together with BPCR Limited Partnership, the “Lenders”), and Biopharma Credit PLC, as collateral agent for the Lenders (in such capacity, the “Collateral Agent), which amends certain terms of the Loan and Security Agreement, dated December 14, 2021, as amended, by and among the Company, Lenders, and Collateral Agent (the “Loan Agreement”). The Second Amendment extends the Company’s option to draw down the second tranche of $50 million of the term loan facility provided under the Loan Agreement until December 31, 2023 (the “Draw Period”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001570562-22-000146","anchor_url":"https://secwatch.observer/filing/0001570562-22-000146#claim-23e2f2e21ba81e12e60b1a74e992d2a91e99b1f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000146/0001570562-22-000146-index.htm"},{"fact_type":"earnings_release","fact_key":"210dfc55d15408613c1cb65fad643dd6144ee865","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2022","report_date":"2022-11-08","result_type":"guidance_update","revenue_text":"$143 to $150 million"},"claim":"Evolus, Inc. reported full-year 2022 results: revenue $143 to $150 million. Guidance reaffirmed.","evidence_excerpt":"the company continues to project full-year 2022 sales at the top end of its guidance range of $143 to $150 million, which includes a minimal contribution from international markets.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-22-000141","anchor_url":"https://secwatch.observer/filing/0001570562-22-000141#claim-210dfc55d15408613c1cb65fad643dd6144ee865","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm"},{"fact_type":"earnings_release","fact_key":"2c0954c7263f33e9b18f3cc2720c481f14ef4f0d","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter ended September 30, 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":"$33.9 million"},"claim":"Evolus, Inc. reported third quarter ended September 30, 2022 results: revenue $33.9 million.","evidence_excerpt":"Total net revenues for the third quarter of 2022 increased 27% to $33.9 million from $26.7 million in the third quarter of 2021 driven almost entirely by higher volumes of Jeuveau","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-22-000141","anchor_url":"https://secwatch.observer/filing/0001570562-22-000141#claim-2c0954c7263f33e9b18f3cc2720c481f14ef4f0d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm"},{"fact_type":"executive_change","fact_key":"fac8071959","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-08-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-05","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Sandra Beaver was appointed as Chief Financial Officer at Evolus, Inc..","evidence_excerpt":"On August 30, 2022, Evolus, Inc. (the “Company”) announced that, effective September 5, 2022, its Board of Directors (the \"Board') appointed Sandra Beaver to serve as the Company’s Chief Financial Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001570562-22-000121","anchor_url":"https://secwatch.observer/filing/0001570562-22-000121#claim-fac8071959","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000121/0001570562-22-000121-index.htm"},{"fact_type":"executive_change","fact_key":"baa914cd90","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-03-04T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2022-05-31","interim":false,"role":"Chief Financial Officer and Executive Vice President, Corporate Development","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Lauren Silvernail departed as Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc..","evidence_excerpt":"On March 3, 2022, Evolus, Inc. (the “Company”) announced that Lauren Silvernail, will retire as the Company’s Chief Financial Officer and Executive Vice President, Corporate Development effective as of May 31, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001570562-22-000071","anchor_url":"https://secwatch.observer/filing/0001570562-22-000071#claim-baa914cd90","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000071/0001570562-22-000071-index.htm"},{"fact_type":"executive_change","fact_key":"4dcc390315","cik":1570562,"ticker":"EOLS","company_name":"Evolus, Inc.","filed_at":"2022-01-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-05","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Brady Stewart was appointed as Director at Evolus, Inc..","evidence_excerpt":"Effective January 5, 2022, the Board of Directors (the “Board”) of Evolus, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee (the “Committee”), appointed Brady Stewart as a member of the Board, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001570562-22-000004","anchor_url":"https://secwatch.observer/filing/0001570562-22-000004#claim-4dcc390315","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000004/0001570562-22-000004-index.htm"}]}